The immunotherapy platform at The University of Texas MD Anderson Cancer Center and the global biopharmaceutical company AbbVie will join forces to find new ways to unleash the immune system’s potential to fight cancer.
The three-year collaboration agreement provides a framework for MD Anderson and AbbVie to efficiently choose and carry out preclinical and clinical studies evaluating new ideas in the cutting-edge area of immuno-oncology...
The University of Texas MD Anderson Cancer Center is grateful Vice President Joe Biden has inspired the creation of a national cancer moonshot...
In cancer, cell signaling pathways are the critical chain of events that can either quash or quicken disease progression.
A multi-institutional...